Aprea Therapeutics (NASDAQ:APRE) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Aprea Therapeutics (NASDAQ:APRE) posted its quarterly earnings data on Monday. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05, Yahoo Finance reports. The firm had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%.

Aprea Therapeutics Stock Down 1.5 %

APRE stock traded down $0.05 during trading on Wednesday, hitting $3.25. 203 shares of the company’s stock traded hands, compared to its average volume of 19,806. The stock has a fifty day moving average price of $3.95 and a two-hundred day moving average price of $5.26. Aprea Therapeutics has a 52 week low of $3.20 and a 52 week high of $8.85. The stock has a market capitalization of $17.65 million, a price-to-earnings ratio of -0.98 and a beta of 1.04.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on APRE. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research note on Monday. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.